Yellow fever vaccination

Yellow fever study : expansion of patient categories

After positive results, the study continues with the inclusion of new patient categories.

The study with adult participants has been completed and the results confirm that for the four WHO prequalified vaccines, injecting only 1/5th of the dose produces a satisfactory immune response comparable to that produced by a standard dose. Following these results, the study continued with the inclusion of a more fragile population, namely HIV+ adults at the Kilifi site, Kenya and children over 5 years of age at the Mbarara site, Uganda. In 250 HIV+ adults and 420 children have been recruited and are currently completing their follow-up.

Newsroom Read more